Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
Mayer EL, Dueck AC, Martin M, Rubovszky G, Burstein HJ, Bellet-Ezquerra M, Miller KD, Zdenkowski N, Winer EP, Pfeiler G, Goetz M, Ruiz-Borrego M, Anderson D, Nowecki Z, Loibl S, Moulder S, Ring A, Fitzal F, Traina T, Chan A, Rugo HS, Lemieux J, Henao F, Lyss A, Antolin Novoa S, Wolff AC, Vetter M, Egle D, Morris PG, Mamounas EP, Gil-Gil MJ, Prat A, Fohler H, Metzger Filho O, Schwarz M, DuFrane C, Fumagalli D, Theall KP, Lu DR, Bartlett CH, Koehler M, Fesl C, DeMichele A, Gnant M. Mayer EL, et al. Among authors: metzger filho o. Lancet Oncol. 2021 Feb;22(2):212-222. doi: 10.1016/S1470-2045(20)30642-2. Epub 2021 Jan 15. Lancet Oncol. 2021. PMID: 33460574 Clinical Trial.
Dissecting the heterogeneity of triple-negative breast cancer.
Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA Jr, Ellis P, Di Leo A, Baselga J, Sotiriou C, Piccart-Gebhart M. Metzger-Filho O, et al. J Clin Oncol. 2012 May 20;30(15):1879-87. doi: 10.1200/JCO.2011.38.2010. Epub 2012 Mar 26. J Clin Oncol. 2012. PMID: 22454417 Review.
Genomic grade adds prognostic value in invasive lobular carcinoma.
Metzger-Filho O, Michiels S, Bertucci F, Catteau A, Salgado R, Galant C, Fumagalli D, Singhal SK, Desmedt C, Ignatiadis M, Haussy S, Finetti P, Birnbaum D, Saini KS, Berlière M, Veys I, de Azambuja E, Bozovic I, Peyro-Saint-Paul H, Larsimont D, Piccart M, Sotiriou C. Metzger-Filho O, et al. Ann Oncol. 2013 Feb;24(2):377-384. doi: 10.1093/annonc/mds280. Epub 2012 Oct 1. Ann Oncol. 2013. PMID: 23028037 Free article.
Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience.
Metzger-Filho O, de Azambuja E, Bradbury I, Saini KS, Bines J, Simon SD, Dooren VV, Aktan G, Pritchard KI, Wolff AC, Smith I, Jackisch C, Lang I, Untch M, Boyle F, Xu B, Baselga J, Perez EA, Piccart-Gebhart M. Metzger-Filho O, et al. Oncologist. 2013;18(2):134-40. doi: 10.1634/theoncologist.2012-0342. Epub 2013 Jan 28. Oncologist. 2013. PMID: 23359433 Free PMC article. Clinical Trial.
CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).
Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, Láng I, Wardley A, Lichinitser M, Sanchez RI, Müller V, Dodwell D, Gelber RD, Piccart-Gebhart MJ, Cameron D. Pestalozzi BC, et al. Among authors: metzger filho o. Lancet Oncol. 2013 Mar;14(3):244-8. doi: 10.1016/S1470-2045(13)70017-2. Epub 2013 Feb 13. Lancet Oncol. 2013. PMID: 23414588
Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial.
Metzger-Filho O, Procter M, de Azambuja E, Leyland-Jones B, Gelber RD, Dowsett M, Loi S, Saini KS, Cameron D, Untch M, Smith I, Gianni L, Baselga J, Jackisch C, Bell R, Sotiriou C, Viale G, Piccart-Gebhart M. Metzger-Filho O, et al. J Clin Oncol. 2013 Jun 1;31(16):1954-60. doi: 10.1200/JCO.2012.46.2440. Epub 2013 Apr 15. J Clin Oncol. 2013. PMID: 23589556 Clinical Trial.
Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study.
Vaz-Luis I, Seah D, Olson EM, Wagle N, Metzger-Filho O, Sohl J, Litsas G, Burstein HJ, Krop IE, Winer EP, Lin NU. Vaz-Luis I, et al. Among authors: metzger filho o. Clin Breast Cancer. 2013 Aug;13(4):254-63. doi: 10.1016/j.clbc.2013.02.010. Clin Breast Cancer. 2013. PMID: 23829891 Free PMC article.
64 results